Amgen, Freeslate In Strategic R&D Alliance

Amgen and Freeslate, Inc., a provider of high throughput research solutions, have entered into a collaboration to leverage Freeslate solutions in addressing aggregation and particulation in protein drug products. The multi-year project will utilize a range of Freeslate products and services, including technology development, high throughput microscale workflows, and Freeslate’s Lab Execution and Analysis (LEA) software.

“As illustrated by this relationship and others we have engaged in over the past year, the formulation of protein therapeutics is a pressing problem for pharmaceutical companies. High throughput research can enable significant steps forward in both understanding and addressing the challenges of aggregation and particulation in protein drug products,” said John Senaldi, chief executive officer of Freeslate. “This is an application area where we are confident in our ability to deliver great value and innovation.”